%0 Journal Article
%T 弥漫大B细胞淋巴瘤的预后影响因素研究进展<br>Research Progress on Prognostic Factors in Diffuse Large B-Cell Lymphoma
%A 邵乐天
%A 李燕
%J Advances in Clinical Medicine
%P 126-130
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/ACM.2024.141018
%X 弥漫大Ｂ细胞淋巴瘤(Diffuse large B cell lymphoma, DLBCL)作为非霍奇金淋巴瘤常见的亚型，具有高度的异质性。目前，迫切需要建立精确的预后模型对DLBCL分层，以开发更加个体化的DLBCL治疗方案。当前广泛应用于临床的预后模型，主要是基于IPI的临床变量。随着病理学、实验室和分子生物学特征对DLBCL患者预后的意义不断加深，可以提高现有模型的分层和预后能力。探索一个最佳的预后模型是目前研究的热点。本文回顾了常见的三种预后模型，分析其存在的缺陷，并对新的临床参数和生物标志物的预后分层价值进行综述。<br />
Diffuse large B-cell lymphoma (Diffuse large B cell lymphoma, DLBCL), as a common subtype of non-Hodgkin’s lymphoma, is highly heterogeneous. At present, it is urgent to establish an accurate prognostic model to stratify DLBCL in order to develop a more individualized treatment plan for DLBCL. At present, the prognosis model which is widely used in clinic is mainly based on the clinical variables of IPI. With the increasing significance of pathological, laboratory and molecular biological characteristics in the prognosis of patients with DLBCL, the stratification and prognostic ability of existing models can be improved. To explore an optimal prognostic model is the focus of the current research. This paper reviews three common prognostic models, analyzes their defects, and reviews the prognostic stratification value of new clinical parameters and biomarkers.
%K 弥漫大B细胞淋巴瘤，预后，预后模型<br>Diffuse Large B Cell Lymphoma
%K Prognosis
%K Prognostic Model
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=78698